Eyeworld

Reference: 1. Upneeq ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%. [Prescribing Information]. Distributed by: RVL Pharmaceuticals, Inc. Bridgewater, NJ 08807 Customer Service 1-866-600-4799 Upneeq is a registered trademark of RVL Pharmaceuticals, Inc. ©2021 RVL Pharmaceuticals, Inc. PM-US-UPN-0197 01/21 Learn more at Upneeq.com PMS 137 C PMS 541 C PMS 908 C PMS 541 C PMS 908 C FONTS RVL: Verdigris MVB Pro Text PHARMACEUTICALS, INC.: Forma DJR Text INDICATION Upneeq ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS • Alpha-adrenergic agonists as a class may impact blood pressure. Advise Upneeq patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens. • Use Upneeq with caution in patients with cerebral or coronary insuffi ciency or Sjögren's syndrome. Advise patients to seek medical care if signs and symptoms of potentiation of vascular insuffi ciency develop. • Upneeq may increase the risk of angle closure glaucoma in patients with untreated narrow-angle glaucoma. Advise patients to seek immediate medical care if signs and symptoms of acute narrow-angle glaucoma develop. • Patients should not touch the tip of the single patient- use container to their eye or to any surface, in order to avoid eye injury or contamination of the solution. ADVERSE REACTIONS Adverse reactions that occurred in 1-5% of subjects treated with Upneeq were punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation, and headache. DRUG INTERACTIONS • Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy. • Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines. To report SUSPECTED ADVERSE REACTIONS or product complaints, contact RVL Pharmaceuticals at 1-877-482-3788. You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Please see next page for Brief Summary of full Prescribing Information. Give Ptosis Patients an EYE-OPENING Lift With a Daily Drop of Upneeq ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% 1 The only FDA-approved prescription eyedrop proven to lift upper eyelids in adults with acquired blepharoptosis (low-lying lids) 1 Learn more at Upneeq.com.

• Blank Page
• Blank Page (1)